Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial Source: Eur Respir J 2013; 41: 556-564 Year: 2013
Direct cost analysis of COPD patients: A 1 year follow-up study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Reduction in asthma-related costs following treatment with montelukast (PRAACTICAL study) Source: Eur Respir J 2005; 26: Suppl. 49, 577s Year: 2005
Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Source: Eur Respir J 2010; 35: 79-87 Year: 2010
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Modelling cost effectiveness of a COPD pathway using the Star approach; could cognitive behavioural therapy (CBT) be cost effective in preventing panic-associated admissions? Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016
NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Budesonide/formoterol adjustable maintenance dosing (AMD) improves health-related quality of life (HRQL) compared with high-dose budesonide (AMD) Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010
Estimating potential cost savings associated with managing COPD according to GOLD 2017 recommendations in UK primary care: a CPRD study Source: International Congress 2018 – COPD management Year: 2018
Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Quality of life (QoL) in asthma 1 year after pulmonary rehabilitation (PR) Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life Year: 2011
Health-related quality of life (HRQL) and patient-reported outcomes (PRO) in COPD patients receiving add-on-therapy with EPs® 7630 Source: Annual Congress 2011 - COPD management Year: 2011
Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study Source: Annual Congress 2009 - New bronchodilators Year: 2009
Number needed to treat (NNT) with budesonide/formoterol to avoid one COPD exacerbation, with cost analysis of treatment Source: Eur Respir J 2004; 24: Suppl. 48, 540s Year: 2004
Improvement of quality of life and cost effectiveness by an outpatient education program for patiens with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 555s Year: 2006
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Cost and effectiveness of 2 years integrated care intervention in COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Effect of salmeterol/fluticasone propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality: INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations) study Source: Eur Respir J 2007; 30: Suppl. 51, 34s Year: 2007